<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01490723</url>
  </required_header>
  <id_info>
    <org_study_id>2011-0393</org_study_id>
    <secondary_id>NCI-2016-00250</secondary_id>
    <nct_id>NCT01490723</nct_id>
  </id_info>
  <brief_title>Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)</brief_title>
  <official_title>Dose-Intense Yttrium-90 Ibritumomab Tiuxetan (Zevalin)-Containing Non-Myeloablative Conditioning for Allogeneic Stem Cell Transplantation in B-cell Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Spectrum Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if adding Zevalin (ibritumomab tiuxetan)
      to low-intensity chemotherapy (the combination of rituximab, bendamustine, and fludarabine),
      followed by an allogeneic stem cell transplant, can help to control lymphoma. The safety of
      this combination will also be studied.

      Two (2) forms of ibritumomab tiuxetan will be used in this study. 90Y-ibritumomab tiuxetan is
      designed to attach to lymphoma cells and destroy the cells using a radioactive particle that
      is attached to it. 111In-ibritumomab tiuxetan is like 90Y- ibritumomab tiuxetan, but the
      radioactive particle that is attached to it does not kill lymphoma cells. The radioactive
      particle makes the drug able to be seen inside your body. It is being used in this study to
      predict how fast the study drug will travel in the body and how long the drug stays in the
      body.

      Rituximab is designed to attach to lymphoma cells, which may cause them to die.

      Bendamustine is designed to damage and destroy the DNA (genetic material) of cancer cells.

      Fludarabine is designed to make cancer cells less able to repair damaged DNA. This may
      increase the likelihood of the cells dying.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Drug Administration and Procedures:

      The chemotherapy, some of the other drugs in this study, and the stem cell transplant will be
      given by vein through your central venous catheter (CVC). A central venous catheter is a
      sterile flexible tube that will be placed into a large vein while you are under local
      anesthesia and will remain in your body during treatment. Your doctor will explain this
      procedure to you in more detail, and you will be required to sign a separate consent form.
      Blood samples will also be drawn through the CVC.

      On Days -22 (22 days before you receive the stem cell transplant), you will receive rituximab
      by vein over 3-4 hours. You will then receive 111In-ibritumomab tiuxetan by vein over 30
      minutes.

      From Day -22 through Day -16, you will have scans called whole-body planar scintigraphy
      imaging. In these scans, a special camera will capture 2-dimensional images of the whole body
      to see where the radioactive 111In- ibritumomab tiuxetan that was injected on Day -22 has
      spread. No additional radiation will be used in this scan. Scintigraphy will be performed
      right after the injection, then 3-6 hours after the injection, then 24, 72, and 144 hours
      (+/- 2 hours) after the injection.

      After the last scintigraphy imaging scan, the scans will be reviewed to learn how much
      radiation has traveled to different organs and to decide how much 90Y- ibritumomab should be
      used.

      On Day-14, you will receive rituximab by vein over 3-4 hours. You will then receive the
      calculated dose of 90Y-ibritumomab tiuxetan by vein over 30 minutes.

      On Days -5, -4, and -3, you will receive fludarabine and bendamustine by vein over 1 hour
      each day.

      On Days -3 through Day 100, if your stem cells are from cord blood, you will receive
      mycophenolate mofetil (MMF) by vein or by mouth. MMF is designed to block the donor cells
      from growing and spreading in a way that could cause graft versus host disease (GVHD -- a
      condition in which transplanted tissue attacks the recipient's body).

      Starting on Day -2, if your stem cells are from a related or matched unrelated donor, you
      will receive tacrolimus by vein as a continuous (nonstop) infusion until you are able to take
      it by mouth to help prevent GVHD. You will then take tacrolimus by mouth 2 times a day for
      about 3 months. After that, your tacrolimus dose may be lowered if you do not have GVHD. Your
      doctor will discuss this with you.

      On Days -2 and -1, if your stems cells are from a matched unrelated donor or from cord blood,
      you will receive thymoglobulin (ATG) by vein over about 4 hours. ATG is designed to weaken
      your immune system to reduce the risk of rejecting of the transplant.

      On Day 0, you will receive the blood stem cells by vein over about 30-45 minutes. Blood (less
      than 1 teaspoon) will also be drawn to measure how much (if any) radiation from the 90Y-
      ibritumomab tiuxetan is left in the blood.

      Starting on Day 0, if your stem cells are from cord blood, you will receive filgrastim
      (G-CSF) through a needle under the skin 1 time a day every day until your white blood count
      begins to recover. G-CSF is designed to help cells in the bone marrow to divide, which helps
      raise white blood cells counts more quickly, lower fever, and decrease the risk of infection.

      On Days 1, 3, and 6, if your stem cells are from a related or matched unrelated donor, you
      will receive methotrexate over 30 minutes each day by vein to help prevent GVHD. Patients
      receiving a matched unrelated donor will also be given methotrexate on Day 11 after the
      transplant.

      Starting on Day 7, if your stem cells are from a related or matched unrelated donor, you will
      receive G-CSF through a needle under the skin 1 time a day every day until your white blood
      count begins to recover.

      When your doctor thinks they are needed, you will also receive antibiotics and antifungal
      drugs to help prevent and/or treat infections. Your doctor will tell you more about how these
      drugs are given and possible side effects.

      You will be in the hospital for about 3-4 weeks after you receive the stem cell transplant.
      During this time, the following tests and procedures will be performed at any point that your
      doctor thinks they are needed:

        -  You will have a physical exam, including measurement of your vital signs (blood
           pressure, heart rate, temperature, and breathing rate).

        -  You will be asked about how you are feeling and about any side effects you may be
           having.

        -  Blood (about 4-6 teaspoons) will be collected for routine tests, to check your kidney
           and liver function, and to learn if and how well the transplant is working.

      The following may also be performed if at any point the doctor thinks they are needed:

        -  You may have imaging scans to check the status of the disease and/or to check for
           possible infections.

        -  You may have a bone marrow biopsy to check the status of the disease. To collect a bone
           marrow biopsy, an area of the hip or other site is numbed with anesthetic, and a small
           amount of bone marrow and bone is withdrawn through a needle.

        -  You may have transfusions of blood and/or platelets.

      You must stay in the Houston area for about 100 days after the stem cell transplant.

      Long-Term Follow-Up:

      About 3, 6, and 12 months after the stem cell transplant:

        -  Blood (about 6 teaspoons) will be collected for routine tests, to check kidney and liver
           function, and to see how well the transplant has taken.

        -  You will have CT and PET scans to check the status of the disease.

        -  You will have a bone marrow biopsy/aspirate to check the status of the disease.

      About 2 and 3 years after the stem cell transplant, you will receive a phone call that will
      take less than 10 minutes to learn how you are doing.

      Length of Study:

      You will be on study for up to about 3 years. You may be taken off study early if the disease
      gets worse, if you have any intolerable side effects, of if you are unable to follow study
      directions.

      You should talk to the study doctor if you want to leave the study early. If you are taken
      off study early, you still may need to return for routine post-transplant follow-up visits,
      if your transplant doctor decides it is needed. It may be life-threatening to leave the study
      after you have begun to receive the study drugs but before you receive the stem cells.

      This is an investigational study. Ibritumomab tiuxetan, rituximab, bendamustine, and
      fludarabine are FDA approved and commercially available for the treatment of lymphoma. The
      dose of ibritumomab tiuxetan in this study is designed to be higher than the FDA approved
      dose. The use of ibritumomab tiuxetan and bendamustine in combination with the other study
      drugs and a stem cell transplant for the treatment of lymphoma is investigational.

      Up to 20 patients will take part in this study. All will be enrolled at MD Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2013</start_date>
  <completion_date type="Actual">April 24, 2019</completion_date>
  <primary_completion_date type="Actual">April 24, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment-Related Mortality (TRM)</measure>
    <time_frame>100 days</time_frame>
    <description>Number of participants without treatment related mortality at day 100.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From date of treatment to date of relapse or death, up to 3 years</time_frame>
    <description>Percentage of participants alive at 3 years.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Yttrium-90 Ibritumomab + Chemo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day -22 and -14, Rituximab 250 mg/m2 preceding 111In Ibritumomab and (90Y) ibritumomab tiuxetan administration, respectively. Day -22, -21 to -16, Imaging, repeated 3-6 hours later (including Single Photon Emission-Computed Tomography/Computed Tomography (SPECT/CT) scan of the abdomen). Day -14, (90Y) ibritumomab tiuxetan administration. Day -5, -4 and -3, Fludarabine and Bendamustine following Stem Cell Transplant (SCT) and CT. Fludarabine 30 mg/m2 intravenously followed by Bendamustine 130 mg/m2 intravenously. All patients receive Graft Versus Host Disease (GvHD) prophylaxis, infections disease prophylaxis, growth factors, blood and platelet transfusion and other supportive treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>250 mg/m2 by vein preceding 111In Ibritumomab and (90Y) ibritumomab tiuxetan administration, respectively on Days -22 and -14.</description>
    <arm_group_label>Yttrium-90 Ibritumomab + Chemo</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>111In Ibritumomab</intervention_name>
    <description>(5.0 mCi +/- 10% of 111In) by vein immediately following the infusion of rituximab on Day -22.</description>
    <arm_group_label>Yttrium-90 Ibritumomab + Chemo</arm_group_label>
    <other_name>Zevalin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Planar Scintigraphy Imaging</intervention_name>
    <description>Day -22, -21 to -16: Planar scintigraphy whole-body imaging started on Day -22 post 111In Ibritumomab infusion prior to voiding, and repeated 3-6 hours later (including Single Photon Emission-Computed Tomography/Computed Tomography (SPECT/CT) scan of the abdomen). Whole-body planar scintigraphy imaging will be repeated between 22-26 hours, then between 70-74 hours, and later between 142-146 hours post 111In Ibritumomab injection.</description>
    <arm_group_label>Yttrium-90 Ibritumomab + Chemo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>90Y IbritumomabTiuxetan</intervention_name>
    <description>Calculated to deliver not below 10 Gy to normal organs (liver, lungs, kidneys) by vein post rituximab on Day -14.</description>
    <arm_group_label>Yttrium-90 Ibritumomab + Chemo</arm_group_label>
    <other_name>Zevalin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>30 mg/m2 intravenously on Days -5, -4, and -3.</description>
    <arm_group_label>Yttrium-90 Ibritumomab + Chemo</arm_group_label>
    <other_name>Fludarabine Phosphate</other_name>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine</intervention_name>
    <description>130 mg/m2 intravenously on D-5, -4 and -3.</description>
    <arm_group_label>Yttrium-90 Ibritumomab + Chemo</arm_group_label>
    <other_name>Bendamustine Hydrochoride</other_name>
    <other_name>Bendamustine HCL</other_name>
    <other_name>CEP-18083</other_name>
    <other_name>SDX-105</other_name>
    <other_name>Treanda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymoglobulin</intervention_name>
    <description>1 mg/kg (based on actual body weight) on Days -2 and -1 will be administrated to patients receiving a cord blood (CB) and a matched unrelated donor (MUD).</description>
    <arm_group_label>Yttrium-90 Ibritumomab + Chemo</arm_group_label>
    <other_name>ATG</other_name>
    <other_name>Antithymocyte Globulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Starting dose of 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml. Tacrolimus is changed to oral dosing when tolerated and can be tapered off after day +90 if no Graft versus Host Disease (GVHD) is present.
For patients receiving cord blood (CB) graft, the Graft versus Host Disease (GvHD) prophylaxis will be with Tacrolimus. Tacrolimus will start on D-2 administrated at starting dose 0.03 mg/kg or 0.015 mg/kg (ideal body weight) by vein starting on D -2 and will be tapered around Day +180 if no GvHD is present.</description>
    <arm_group_label>Yttrium-90 Ibritumomab + Chemo</arm_group_label>
    <other_name>Prograf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>5 mg/m2 by vein on Day +1, +3 and +6. Patients receiving an unrelated graft will also be given methotrexate on Day +11 after the transplant.</description>
    <arm_group_label>Yttrium-90 Ibritumomab + Chemo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate</intervention_name>
    <description>15 mg/kg (actual body weight with a maximum dose of 1 gram twice daily) by vein or by mouth administered from Days -3 to +45 and then tapered to end by day 100 if there is no Graft versus Host Disease (GVHD).</description>
    <arm_group_label>Yttrium-90 Ibritumomab + Chemo</arm_group_label>
    <other_name>MMF</other_name>
    <other_name>Mycophenolate Mofetil</other_name>
    <other_name>CellCept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF</intervention_name>
    <description>5 mcg/kg/day subcutaneously beginning Day +7 for patients receiving related and matched unrelated donor (MUD) grafts and on Day 0 for patients receiving a cord blood (CB). G-CSF will continue until the absolute neutrophil count (ANC) is &gt; 500 * 10/L for 3 consecutive days.</description>
    <arm_group_label>Yttrium-90 Ibritumomab + Chemo</arm_group_label>
    <other_name>Filgrastim</other_name>
    <other_name>Neupogen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stem Cell Transplantation</intervention_name>
    <description>Stem Cell Transplantation on Day 0</description>
    <arm_group_label>Yttrium-90 Ibritumomab + Chemo</arm_group_label>
    <other_name>Allogeneic transplantation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 to 70 years of age.

          2. Patients with the following CD20+ lymphoid malignancies who are eligible for
             allogeneic transplantation: a. Relapsed or refractory follicular lymphoma; b. Relapsed
             or refractory or high risk mantle cell lymphoma (hi ki67; blastic); c. Recurrent or
             refractory marginal zone; d. Recurrent or refractory CLL/small lymphocytic lymphoma;
             e. Double-hit lymphoma; f. Diffuse large B cell lymphoma; g. Richter's patients; or h.
             Refractory or recurrent Burkitts.

          3. Patients who meet criterion #2 or have any of the following are eligible: a. Less than
             PR to salvage chemotherapy; b. Kinetic failure; c. Having received more than 3 lines
             of therapy; d. Failure to mobilize autologous stem cell; e. 10% or more marrow
             involvement; f. 6 months post autologous stem cell transplant.

          4. Patients must have a fully-matched related donor or a matched unrelated donor
             identified. Double cord (at least 4/6 matched) can be used if no adult matched donor
             is available.

          5. Performance score of at least 80% by Karnofsky or 0 to 2 ECOG.

          6. Left ventricular EF &gt;/= 45% with no uncontrolled arrythmias or symptomatic heart
             disease.

          7. FEV1, FVC &gt;/= 60% and corrected DLCO &gt;/= 60%.

          8. Serum creatinine &lt;/=1.6 mg/dL. Serum bilirubin &lt; 2 mg/dL (unless due to Gilbert's
             Syndrome).

          9. SGPT &lt; 2 X upper limit of normal.

         10. Men and women of reproductive potential must agree to follow accepted birth control
             methods (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with
             spermicide, condom with spermicide, or abstinence) for the duration of the study.

         11. Negative Beta HCG test within 30 days in a woman with child bearing potential defined
             as not post-menopausal for 12 months or no previous surgical sterilization). Pregnancy
             testing is not required for post-menopausal or surgically sterilized women.

        Exclusion Criteria:

          1. Patient with active CNS involvement with lymphoid malignancy.

          2. Known infection with HIV, HTLV-I, Hepatitis B, or Hepatitis C.

          3. Patients with other malignancies diagnosed within 2 years prior to study registration.
             Skin squamous or basal cell carcinoma are exceptions.

          4. Active bacterial, viral or fungal infections.

          5. History of stroke within 6 months prior to study registration.

          6. A prior allogeneic stem cell transplant.

          7. Patient has received other investigational drugs within 3 weeks before study
             registration.

          8. Presence of circulating malignant lymphoid cells or bone marrow with lymphoma that
             constituted more than 25% of the cellular elements.

          9. Serious nonmalignant or malignant disease or psychiatric illness, which, in the
             opinion of the investigator would compromise protocol objectives or interfere with
             participation.

         10. Patients who are breast-feeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Issa F. Khouri, MD,BS</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>December 9, 2011</study_first_submitted>
  <study_first_submitted_qc>December 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2011</study_first_posted>
  <results_first_submitted>April 13, 2020</results_first_submitted>
  <results_first_submitted_qc>April 23, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">May 5, 2020</results_first_posted>
  <last_update_submitted>April 23, 2020</last_update_submitted>
  <last_update_submitted_qc>April 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leukemia</keyword>
  <keyword>Chronic lymphocytic leukemia</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>CD20+ lymphoid malignancies</keyword>
  <keyword>Diffuse large B-cell lymphoma</keyword>
  <keyword>Allogeneic transplantation</keyword>
  <keyword>Rituximab</keyword>
  <keyword>Rituxan</keyword>
  <keyword>In ibritumomab</keyword>
  <keyword>Y ibritumomab</keyword>
  <keyword>Zevalin</keyword>
  <keyword>Fludarabine Phosphate</keyword>
  <keyword>Fludara</keyword>
  <keyword>Bendamustine Hydrochloride</keyword>
  <keyword>Bendamustine HCL</keyword>
  <keyword>CEP-18083</keyword>
  <keyword>SDX-105</keyword>
  <keyword>Treanda</keyword>
  <keyword>Stem Cell Transplantation</keyword>
  <keyword>Planar Scintigraphy</keyword>
  <keyword>Spect Scan</keyword>
  <keyword>Single Photon Emission-Computed Tomography</keyword>
  <keyword>CT Scan</keyword>
  <keyword>Computed Tomography</keyword>
  <keyword>G-CSF</keyword>
  <keyword>Filgrastim</keyword>
  <keyword>Neupogen</keyword>
  <keyword>Thymoglobulin</keyword>
  <keyword>ATG</keyword>
  <keyword>Antithymocyte Globulin</keyword>
  <keyword>Methotrexate</keyword>
  <keyword>Mycophenolate</keyword>
  <keyword>MMF</keyword>
  <keyword>Mycophenolate Mofetil</keyword>
  <keyword>CellCept</keyword>
  <keyword>Tacrolimus</keyword>
  <keyword>Prograf</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 2, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/23/NCT01490723/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Yttrium-90 Ibritumomab + Chemo</title>
          <description>Day -22 and -14, Rituximab 250 mg/m2 preceding In Ibritumomab and ibritumomab tiuxetan administration, respectively. Day -22, -21 to -16, Imaging, repeated 3-6 hours later (including Single Photon Emission-Computed Tomography/Computed Tomography (SPECT/CT) scan of the abdomen). Day -14,ibritumomab tiuxetan administration. Day -5, -4 and -3, Fludarabine and Bendamustine following Stem Cell Transplant (SCT) and CT. Fludarabine 30 mg/m2 intravenously followed by Bendamustine 130 mg/m2 intravenously. All patients receive Graft Versus Host Disease (GvHD) prophylaxis, infections disease prophylaxis, growth factors, blood and platelet transfusion and other supportive treatment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Yttrium-90 Ibritumomab + Chemo</title>
          <description>Day -22 and -14, Rituximab 250 mg/m2 preceding In Ibritumomab and ibritumomab tiuxetan administration, respectively. Day -22, -21 to -16, Imaging, repeated 3-6 hours later (including Single Photon Emission-Computed Tomography/Computed Tomography (SPECT/CT) scan of the abdomen). Day -14,ibritumomab tiuxetan administration. Day -5, -4 and -3, Fludarabine and Bendamustine following Stem Cell Transplant (SCT) and CT. Fludarabine 30 mg/m2 intravenously followed by Bendamustine 130 mg/m2 intravenously. All patients receive Graft Versus Host Disease (GvHD) prophylaxis, infections disease prophylaxis, growth factors, blood and platelet transfusion and other supportive treatment.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Treatment-Related Mortality (TRM)</title>
        <description>Number of participants without treatment related mortality at day 100.</description>
        <time_frame>100 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Yttrium-90 Ibritumomab + Chemo</title>
            <description>Day -22 and -14, Rituximab 250 mg/m2 preceding In Ibritumomab and ibritumomab tiuxetan administration, respectively. Day -22, -21 to -16, Imaging, repeated 3-6 hours later (including Single Photon Emission-Computed Tomography/Computed Tomography (SPECT/CT) scan of the abdomen). Day -14,ibritumomab tiuxetan administration. Day -5, -4 and -3, Fludarabine and Bendamustine following Stem Cell Transplant (SCT) and CT. Fludarabine 30 mg/m2 intravenously followed by Bendamustine 130 mg/m2 intravenously. All patients receive Graft Versus Host Disease (GvHD) prophylaxis, infections disease prophylaxis, growth factors, blood and platelet transfusion and other supportive treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment-Related Mortality (TRM)</title>
          <description>Number of participants without treatment related mortality at day 100.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>Percentage of participants alive at 3 years.</description>
        <time_frame>From date of treatment to date of relapse or death, up to 3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Yttrium-90 Ibritumomab + Chemo</title>
            <description>Day -22 and -14, Rituximab 250 mg/m2 preceding In Ibritumomab and ibritumomab tiuxetan administration, respectively. Day -22, -21 to -16, Imaging, repeated 3-6 hours later (including Single Photon Emission-Computed Tomography/Computed Tomography (SPECT/CT) scan of the abdomen). Day -14,ibritumomab tiuxetan administration. Day -5, -4 and -3, Fludarabine and Bendamustine following Stem Cell Transplant (SCT) and CT. Fludarabine 30 mg/m2 intravenously followed by Bendamustine 130 mg/m2 intravenously. All patients receive Graft Versus Host Disease (GvHD) prophylaxis, infections disease prophylaxis, growth factors, blood and platelet transfusion and other supportive treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>Percentage of participants alive at 3 years.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to 3 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Yttrium-90 Ibritumomab + Chemo</title>
          <description>Day -22 and -14, Rituximab 250 mg/m2 preceding In Ibritumomab and ibritumomab tiuxetan administration, respectively. Day -22, -21 to -16, Imaging, repeated 3-6 hours later (including Single Photon Emission-Computed Tomography/Computed Tomography (SPECT/CT) scan of the abdomen). Day -14,ibritumomab tiuxetan administration. Day -5, -4 and -3, Fludarabine and Bendamustine following Stem Cell Transplant (SCT) and CT. Fludarabine 30 mg/m2 intravenously followed by Bendamustine 130 mg/m2 intravenously. All patients receive Graft Versus Host Disease (GvHD) prophylaxis, infections disease prophylaxis, growth factors, blood and platelet transfusion and other supportive treatment.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Left ventricular systolic dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Infections and Infestations</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thromboembolic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Thromboembolic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Issa F. Khouri, M.D., Stem Cell Transplantation</name_or_title>
      <organization>U.T. MD Anderson Cancer Center</organization>
      <phone>(713) 745-0049</phone>
      <email>ikhouri@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

